Navigation Links
ISTO To Present At Upcoming Conferences
Date:11/26/2013

ST. LOUIS, Nov. 26, 2013 /PRNewswire/ -- ISTO Technologies, Inc., a privately-held regenerative medicine company, announced today that Mitchell Seyedin, Ph.D., the Company's President and Chief Executive Officer, will present at the following upcoming investor conferences:

  • The 25th Annual Piper Jaffray Healthcare Conference
    The New York Palace in New York City
    Presentation: Wednesday, December 4, 2013, 11:50 a.m. EST
  • The 24th Annual Oppenheimer Healthcare Conference
    The Crowne Plaza Hotel in New York City
    Presentation: Tuesday, December 10, 2013 at 10:55 a.m. EST

About ISTO Technologies, Inc. 

ISTO is a privately-held orthobiologics company dedicated to improving patient quality of life through the development of proprietary products for spinal therapies and sport medicine applications. ISTO's products are intended for the repair and regeneration of damaged or injured cartilage and bone. The Company's proprietary cell-based orthobiologic platform harnesses the regenerative capacity of juvenile cartilage cells to create products designed to repair and restore function to damaged cartilage tissue. In addition to cell-based cartilage products in clinical development, ISTO manufactures and markets InQu®, a bone graft extender and substitute for spinal fusion applications that has been used in over 28,000 surgeries at U.S. hospitals to date. For additional information on ISTO, please visit our website at www.istotech.com.


'/>"/>
SOURCE ISTO Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Burzynski Clinic Presents the Results of Phase II Study of Antineoplastons in Children with Recurrent High-Grade Glioma at the Congress
2. Neurocrine Biosciences To Present At Deutsche Bank 2013 Biofest And The 25th Annual Piper Jaffray Healthcare Conference
3. Sangamo BioSciences Announces Presentation At The 25th Annual Piper Jaffray Healthcare Conference
4. Venaxis to Present at Piper Jaffray 25th Annual Healthcare Conference
5. Dyadic International To Present At Two Major Conferences In December 2013
6. Sangamo BioSciences Announces Seven Data Presentations At The 2013 American Society of Hematology Annual Meeting
7. Aratana Therapeutics to Present at Two Upcoming Investor Conferences
8. Celladon Corporation Announces Oral Presentation at American Heart Association of Long Term Follow-Up Results from the MYDICAR CUPID 1 Trial in Advanced Heart Failure
9. Amgen Presents Interim Overall Survival Data From Phase 3 Study Of Talimogene Laherparepvec In Patients With Metastatic Melanoma
10. Accuray to Present at Piper Jaffray 25th Annual Healthcare Conference
11. Cartes 2013: DERMALOG Presents World Firsts in Biometrics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... 2014 Respiratory therapy students will ... management of life-like respiratory ailments using the latest ... Grand Rapids-based, Michigan Instruments Inc. developers of the ... the respiratory simulation units to the pro-gram, which ... and Muskegon Community College are collaborating to offer ...
(Date:11/21/2014)... USA (PRWEB) November 19, 2014 The ... our lives was shared with more than 200 primary ... postgraduate students from the University of Otago Physics Department ... . The Otago students, members of the university’s OSA/SPIE ... Zealand in early September, giving children from small, rural ...
(Date:11/21/2014)... NY (PRWEB) November 20, 2014 The ... now available as an open access journal featuring the ... infrared fluorescent proteins to preserve photoresponsiveness in the retina ... Two-color fluorescent in situ hybridization using chromogenic substrates in ... for DNA, RNA, and protein electrophoresis , ...
(Date:11/21/2014)... , Nov. 20, 2014 Polaris Group ... dosed in its Phase 1 trial of ADI-PEG ... the treatment of malignant pleural mesothelioma (MPM) and ... conducting clinical trials on ADI-PEG 20, both as ... the treatment of several other indications, including breast ...
Breaking Biology Technology:Michigan Instruments Donates Two Respiratory Simulation Training and Test Lung (TTL) Devices to Grand Valley State University 2Michigan Instruments Donates Two Respiratory Simulation Training and Test Lung (TTL) Devices to Grand Valley State University 3Optics and photonics outreach programs share science, spark fascination with light 2Optics and photonics outreach programs share science, spark fascination with light 3BioTechniques: The International Journal of Life Science Methods Announces the Publication of the November 2014 Issue—Available in Print and Online 2BioTechniques: The International Journal of Life Science Methods Announces the Publication of the November 2014 Issue—Available in Print and Online 3Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma 2
... , June 1 /PRNewswire/ -- Pioneer Surgical Technology, ... follow up on the NuBac IDE feasibility study patients was presented at ... of Spine Surgery (SAS) in New Orleans by Domagoj ... , , ...
... June 1 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ... has received approval from the Belgian Federal Agency for ... 3 trial examining REOLYSIN in combination with paclitaxel and ... This is the same trial that was agreed to ...
... BOZEN, Sud-Tirol, Italy , May ... joint venture Health Robotics South East Asia Ltd.,scored two ... to deliver CytoCare-made accurate and sterile,oncology patient doses in ... Health,Robotics, CytoCare is the first and only robot in ...
Cached Biology Technology:Two-Year Follow up Data of NuBac® IDE Feasibility Study Was Presented at SAS Meeting 2Oncolytics Biotech(R) Inc. Receives Approval from Belgium FAMHP to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers 2Oncolytics Biotech(R) Inc. Receives Approval from Belgium FAMHP to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers 3Oncolytics Biotech(R) Inc. Receives Approval from Belgium FAMHP to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers 4Health Robotics South East Asia Wins two key Cancer Therapy Outsourcing Projects in Malaysia and Thailand 2Health Robotics South East Asia Wins two key Cancer Therapy Outsourcing Projects in Malaysia and Thailand 3
(Date:11/21/2014)... 2014 C-Labs LLC, a leading provider of ... (IoT), today announced the appointment of John Traynor ... a strategic advisor to the firm, Mr. Traynor will ... is based out of the C-Labs office in ... Chris Muench , Chief Executive Officer. Photo ...
(Date:11/18/2014)... Nov. 18, 2014   EyeLock Inc. , ... and MorphoTrust USA (Safran), a leading ... announced a strategic partnership to offer comprehensive biometric ... administration (MVA), airport screening and financial services markets. ... MorphoTrust serves consumers through a nationwide network of ...
(Date:11/7/2014)... Debra Auguste, associate professor, biomedical engineering, in the ... of New York, have identified a molecule that ... the most aggressive forms of breast cancer. , ... mortality rate owing to aggressive proliferation and metastasis ... Professor Auguste,s team, discovered the overexpression of intercellular ...
Breaking Biology News(10 mins):C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3
... School of Medicine have found that new disease pathways ... 1 Gaucher disease, a rare genetic disorder in which ... liver/spleen enlargement, osteoporosis, bone pain, and increased risk of ... could lead to less expensive and more effective ways ...
... the cure for a fungus and parasite that affects millions ... of Missouri Chemistry Professor John Tanner would be the forensic ... model that could eventually solve the crime. Tanner, who also ... joined forces with Pablo Sobrado, an assistant professor of biochemistry ...
... CHAMPAIGN, Ill. University of Illinois chemists have ... in shoe bombs. It could lead to inexpensive, easy-to-use ... elsewhere. Triacetone triperoxide (TATP) is a high-powered explosive ... bombing attempts. TATP is easy to prepare from readily ...
Cached Biology News:Cheaper, more effective treatment of type 1 Gaucher disease possible 2X-ray diffraction may play key role in stopping 'kissing bug,' fungus 2Sniffing out shoe bombs: A new and simple sensor for explosive chemicals 2